We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Alligator Bioscience

News List

Alligator Bioscience signs antibody agreement for Greater China biospectrumasia
August 22, 2019
Alligator has granted Biotheus rights in Greater China to an antibody from ALLIGATOR-GOLD® for the creation of up to three bispecific molecules.
Alligator Bioscience regains cancer asset rights from Janssen pharmaceutical-technology
August 01, 2019
Swedish biotech firm Alligator Bioscience has regained the global rights for tumour-directed immunotherapy ADC-1013 (JNJ-64457107) from Janssen Biotech.
Aptevo, Alligator in Bispecific Antibody Development Pact contractpharma
July 24, 2017
Aptevo Therapeutics Inc. and Alligator Bioscience have entered into an agreement to co-develop an immunotherapy bispecific antibody candidate, ALG.APV-527, based on Alligator’s first generation bispecific antibody, ATOR-1016.